ATE201993T1 - Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie - Google Patents
Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämieInfo
- Publication number
- ATE201993T1 ATE201993T1 AT98302794T AT98302794T ATE201993T1 AT E201993 T1 ATE201993 T1 AT E201993T1 AT 98302794 T AT98302794 T AT 98302794T AT 98302794 T AT98302794 T AT 98302794T AT E201993 T1 ATE201993 T1 AT E201993T1
- Authority
- AT
- Austria
- Prior art keywords
- olnzapine
- treatment
- production
- medicinal product
- focal ischemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- External Artificial Organs (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Eye Examination Apparatus (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4309597P | 1997-04-15 | 1997-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE201993T1 true ATE201993T1 (de) | 2001-06-15 |
Family
ID=21925477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98302794T ATE201993T1 (de) | 1997-04-15 | 1998-04-09 | Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0872239B1 (de) |
| AT (1) | ATE201993T1 (de) |
| AU (1) | AU6896198A (de) |
| DE (1) | DE69800906T2 (de) |
| DK (1) | DK0872239T3 (de) |
| ES (1) | ES2158647T3 (de) |
| GR (1) | GR3036260T3 (de) |
| PT (1) | PT872239E (de) |
| SI (1) | SI0872239T1 (de) |
| WO (1) | WO1998046230A1 (de) |
| ZA (1) | ZA982917B (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1155696B1 (de) * | 1997-04-15 | 2004-03-03 | Eli Lilly And Company | Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion |
| WO2002013870A2 (en) * | 2000-08-17 | 2002-02-21 | Mitokor, Inc. | Formulation for administering therapeutic lipophilic molecules |
| ES2303462B1 (es) * | 2004-09-06 | 2009-06-05 | Shasun Chemicals And Drugs Limited | Nuevo procedimiento para la preparacion de una forma polimorfica i de olanzapina farmaceuticamente pura. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5605911A (en) * | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
| US5631250A (en) * | 1995-03-24 | 1997-05-20 | Eli Lilly And Company | Process and solvate of 2-methyl-thieno-benzodiazepine |
| US5637584A (en) * | 1995-03-24 | 1997-06-10 | Eli Lilly And Company | Solvate of olanzapine |
| EG23659A (en) * | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
| US5696115A (en) * | 1995-04-21 | 1997-12-09 | Eli Lilly And Company | Method for treating nicotine withdrawal |
| US5744470A (en) * | 1996-03-11 | 1998-04-28 | Eli Lilly And Company | Method for treating insomnia |
-
1998
- 1998-04-06 ZA ZA9802917A patent/ZA982917B/xx unknown
- 1998-04-08 WO PCT/US1998/007154 patent/WO1998046230A1/en active Application Filing
- 1998-04-08 AU AU68961/98A patent/AU6896198A/en not_active Abandoned
- 1998-04-09 DE DE69800906T patent/DE69800906T2/de not_active Expired - Fee Related
- 1998-04-09 PT PT98302794T patent/PT872239E/pt unknown
- 1998-04-09 DK DK98302794T patent/DK0872239T3/da active
- 1998-04-09 SI SI9830045T patent/SI0872239T1/xx unknown
- 1998-04-09 EP EP98302794A patent/EP0872239B1/de not_active Expired - Lifetime
- 1998-04-09 ES ES98302794T patent/ES2158647T3/es not_active Expired - Lifetime
- 1998-04-09 AT AT98302794T patent/ATE201993T1/de not_active IP Right Cessation
-
2001
- 2001-07-24 GR GR20010401109T patent/GR3036260T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998046230A1 (en) | 1998-10-22 |
| ES2158647T3 (es) | 2001-09-01 |
| EP0872239B1 (de) | 2001-06-13 |
| PT872239E (pt) | 2001-09-28 |
| EP0872239A2 (de) | 1998-10-21 |
| EP0872239A3 (de) | 1998-10-28 |
| ZA982917B (en) | 1999-10-06 |
| SI0872239T1 (en) | 2001-10-31 |
| DK0872239T3 (da) | 2001-09-03 |
| GR3036260T3 (en) | 2001-10-31 |
| DE69800906D1 (de) | 2001-07-19 |
| AU6896198A (en) | 1998-11-11 |
| DE69800906T2 (de) | 2001-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2160124T3 (es) | Utilizacion de bcl-2 para la fabricacion de medicamentos para el tratamiento terapeutico y la prevencion de enfermedades. | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| DE69736441D1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
| DE69331605D1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
| ATE137965T1 (de) | Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege | |
| NO944339D0 (no) | Melatoninderivater for anvendelse ved behandling av sövnforstyrrelser | |
| ATE239470T1 (de) | Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen | |
| DE69733169D1 (de) | Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs | |
| ATE201993T1 (de) | Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie | |
| DE69307702D1 (de) | Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit | |
| DE69733321D1 (de) | Olanzapine zur behandlung von drogenmissbrauch | |
| ATE245421T1 (de) | Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten | |
| ATE260662T1 (de) | Verwendung von olanzapin zur herstellung eines arzneimittels zur neuroprotektion | |
| EA199800820A1 (ru) | Способ лечения злоупотребления лекарственными средствами |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REN | Ceased due to non-payment of the annual fee |